A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Panic Disorder
Interventions
DRUG

quetiapine XR

Subjects will receive daily dosing at night, with a flexible dosing schedule, 50-400 mg.

DRUG

placebo

Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.

Trial Locations (1)

46202

University Hospital Outpatient Center, Psychiatry, Indianapolis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Indiana University

OTHER